- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22:05 | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| PSYENCE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 28.08. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 04.08. | Psyence Biomedical Ltd.: Corporate Update, August 2025 | 223 | GlobeNewswire (Europe) | NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- From Dr. Neil Maresky, CEO, Psyence BioMed (NASDAQ: PBM) Dear Shareholders, Thank you for your continued support as we advance our mission to develop safe... ► Artikel lesen | |
| 01.08. | Pre-market Movers: Namib Minerals, 4D Molecular Therapeutics, CCC Intelligent Solutions, Enovix, Psyence Biomedical | 644 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.25 A.M. ET).In the Green Namib Minerals (NAMM) is up over 108% at $8.26.
4D... ► Artikel lesen | |
| 31.07. | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | 548 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| 31.07. | Psyence Biomedical stock soars after partner achieves ibogaine breakthrough | 15 | Investing.com | ||
| 31.07. | Psyence Biomedical Ltd.: Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production | 176 | GlobeNewswire (Europe) | NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") is pleased to announce that its strategic partner, PsyLabs - a leader in the production... ► Artikel lesen | |
| 23.07. | PSYENCE BIOMEDICAL LTD. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 20-F, Annual and transition report of foreign private issuers | 1 | SEC Filings | ||
| 25.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 18.06. | Psyence Biomedical Ltd.: Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025 | 350 | Newsfile | Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's... ► Artikel lesen | |
| 17.06. | Psyence BioMed regains Nasdaq compliance following reverse stock split | 1 | Seeking Alpha | ||
| 17.06. | Psyence Biomedical regains Nasdaq compliance after reverse split | 4 | Investing.com | ||
| 17.06. | Psyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements | 265 | Newsfile | New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq... ► Artikel lesen | |
| 11.06. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | Psyence BioMed advances Phase IIb psilocybin trial with new CRO partnershi | 2 | Investing.com | ||
| 27.05. | Psyence Biomedical Ltd.: Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial | 360 | Newsfile | New York, New York--(Newsfile Corp. - May 27, 2025) - Psyence BioMed (NASDAQ: PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company developing nature-derived psilocybin therapies for... ► Artikel lesen | |
| 20.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.05. | PSYENCE BIOMEDICAL LTD. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.05. | Psyence Biomedical to execute 1-for-7.97 reverse stock split | 5 | Seeking Alpha |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOLINERX | 2,790 | -2,96 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 10,970 | +4,48 % | Transcode Therapeutics, Inc. - 8-K, Current Report | ||
| SILEXION THERAPEUTICS | 7,140 | 0,00 % | Silexion beauftragt AMS als CRO-Partner für klinische Studien zur KRAS-Krebstherapie | ||
| MINK THERAPEUTICS | 12,200 | +4,27 % | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| BIONTECH | 96,05 | +7,98 % | BioNTech erreicht Phase-3-Erfolg bei Brustkrebsstudie mit BNT323 | BioNTech hat gemeinsam mit DualityBio einen wichtigen Studienerfolg erzielt: In einer von DualityBio in China durchgeführten Phase-3-Studie erreichte der Antikörper-Wirkstoff-Kandidat Trastuzumab Pamirtecan... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | dpa-AFX-Überblick: UNTERNEHMEN vom 29.08.2025 - 15.15 Uhr | ROUNDUP: Gerresheimer bekommt überraschend neuen Finanzchef - Aktie erholt DÜSSELDORF - Der zuletzt schwächelnde Pharmaverpackungshersteller Gerresheimer bekommt überraschend einen neuen Finanzchef.... ► Artikel lesen | |
| EVOTEC | 5,856 | +2,70 % | Evotec Aktie: Bringt der "Insiderkauf" die große Kurs-Wende? | Ein großer "Insiderkauf" machte bei der Evotec Aktie in dieser Woche Schlagzeilen. Wer dachte, dass der Aktienkauf des CEO von Evotec im Wert von knapp 0,3 Millionen Euro aber massive Dynamik in die... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 50,38 | +3,81 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,980 | +9,14 % | Summit Therapeutics stock maintains Buy rating at H.C. Wainwright on ivonescimab progress | ||
| BEAM THERAPEUTICS | 20,890 | +12,55 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| VERA THERAPEUTICS | 24,220 | +10,59 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 34,750 | +4,75 % | Mineralys reports positive subgroup data for hypertension drug | ||
| ARS PHARMACEUTICALS | 10,090 | -5,52 % | Roth/MKM initiates ARS Pharmaceuticals stock with Buy rating on neffy potential | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 59,42 | -0,50 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| FORTRESS BIOTECH | 3,690 | +29,70 % | Fortress Biotech, Inc.: Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right... ► Artikel lesen |
Das Unternehmen PSYENCE BIOMEDICAL LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,490 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PSYENCE BIOMEDICAL LTD finden Sie auf Wallstreet Online.